Evidence map›Paper›PMID 30881117›Full record

ArticleCancer management and research2019

Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis.

Xu-Ping Gao, Yan-Hua Liu, Ze-Ying Liu, Li-Jun Wang, Chun-Xia Jing, Sui Zhu, Fang-Fang Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. SYSTEMIC INFLAMMATORY MARKERS - PROGNOSTIC VALUE IN OVARIAN CANCER.Acta endocrinologica (Bucharest, Romania : 2005)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xu-Ping GaoDepartment of Epidemiology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China, zengffjnu@126.com.
Yan-Hua LiuDepartment of Nutrition, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
Ze-Ying LiuDepartment of Epidemiology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China, zengffjnu@126.com.
Li-Jun WangDepartment of Nutrition, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China.
Chun-Xia JingDepartment of Epidemiology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China, zengffjnu@126.com.
Sui ZhuDepartment of Medical Statistics, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China, zhusui1213@126.com.
Fang-Fang ZengDepartment of Epidemiology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China, zengffjnu@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn this meta-analysis, we analyzed retrospective cohort studies that assessed the prognostic potential of the pretreatment lymphocyte-to-monocyte ratio (LMR) among patients with ovarian cancer (OC). MATERIALS AND

methodsWe comprehensively searched electronic databases, including PubMed and Embase, from inception through October 2018. A random-effects model was used to calculate pooled HRs and their 95% CIs for overall survival (OS) and progression-free survival (PFS). The low LMR group was treated as the reference group.

resultsTwelve studies, including 3,346 OC cases at baseline, were included. Overall, our results indicated that LMR was positively associated with both OS (HR: 1.85, 95% CI: 1.50-2.28,

conclusionThis study suggested that a higher pretreatment LMR level was associated with a favorable prognosis among OC patients. Future large-scale prospective clinical trials are needed to confirm the prognostic value of LMR among OC patients.

Indexed as

lymphocyte-to-monocyte ratiometa-analysisovarian cancerprognosis

Identifiers

PMID30881117
PMCPMC6398401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.